Deceuninck N.V. (0MEL)
London Exchange · UK · prices in EUR · close of 20 Oct 2026
Key indicators
| Last close | EUR 2.375 |
|---|---|
| 52-week range | 1.910 – 2.535 |
| Return, 1 month / 3 months | −4.6% / +7.5% |
| Return, 1 year / 3 years | +17.5% / +8.7% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 38 |
| Volatility (1 year) | 29.2% |
| Worst drawdown (1 year) | -19.9% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | 2.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Deceuninck is a Belgian manufacturer of window and door systems, working mainly in PVC and aluminium profiles. It supplies profile systems and related building products, including roofline, cladding and decking, to fabricators, installers and builders. The company is based in Hooglede-Gits, Belgium, and serves customers in Europe and other markets. Its products are used in residential and commercial construction, where the focus is on durable frames and energy-efficient glazing systems.
Deceuninck N.V. trades under the code 0MEL on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Deceuninck N.V. (0MEL) trades on the London Exchange in UK. It last closed at EUR 2.375 on 20 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 1,198 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 17.5% and over the last three months it rose 7.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 74 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 7.2% | ||
| From 52-week high | -6.3% | ||
| Momentum | 73 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 7.5% | ||
| 6-month return | 11.6% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 69 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.9% | ||
| Liquidity | 13 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 1.7% | ||
| Income | 54 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.7% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −3.1% |
|---|---|
| 1 month | −4.6% |
| 3 months | +7.5% |
| 6 months | +11.6% |
| 1 year | +17.5% |
| 3 years | +8.7% |
| 5 years | – |
Signals
| 50-day / 200-day average | 2.408 / 2.215 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.029 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 May 2026 | EUR 0.0630 |
| 2 May 2025 | EUR 0.0560 |
| 3 May 2024 | EUR 0.0560 |
| 5 May 2023 | EUR 0.0490 |
| 9 May 2022 | EUR 0.0420 |
| 10 May 2021 | EUR 0.0350 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.